PROEHL GERALD T - 02 Jan 2026 Form 4 Insider Report for Dermata Therapeutics, Inc. (DRMA)

Reporting relationship: President, CEO and Chairman, Director, 10%+ Owner
Issuer ticker: DRMA
Reported as of: 02 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Jan 2026, 20:00:13 UTC
Prior SEC filing: 29 Dec 2025
Next SEC filing: 13 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Gerald T. Proehl

Key filing fact

PROEHL GERALD T filed Form 4 for Dermata Therapeutics, Inc. (DRMA) on 06 Jan 2026.

Key facts

This page summarizes PROEHL GERALD T's Form 4 filing for Dermata Therapeutics, Inc. (DRMA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 06 Jan 2026, 20:00.

Change

Previous filing in this sequence was filed on 29 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001279191 Primary reporting owner

PROEHL GERALD T

Relationship: President, CEO and Chairman, Director, 10%+ Owner
Address: 3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO
Signature: /s/ Gerald T. Proehl
Signature date: 06 Jan 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

DRMA transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +37,500
Change %
Price: $0.000000
Shares after: 37,500
Date: 02 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 37,500
Exercise price: $2.18
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares underlying the option will vest as to 25% upon the 12 month anniversary of the grant date, and will vest as to 75% in 36 equal monthly installments commencing on the 12 month anniversary of the grant date.